References
- URL: http://AtlasGeneticsOncology.org/Anomalies/MMULID2038.html
- Zandcki M. Multiple myeloma: almost all patients are cytogeneti-cally abnormal. Br J Haematol 1996; 94(2): 217–227.
- Pantou D, Rizou H, Tsarouha H. Cytogenetic manifestations of multiple myeloma heterogeneity. Genes Chromosomes Cancer 2005; 42(1): 44–57.
- Yilmaz Z, Sahin Fl, Kizilkilic E. Conventional and molecular cytogenetic findings of myelodysplastic syndrome patients. Clin Exp Med 2005; 5(2): 55–59.
- Sahin Fl, Kizilkilic E, Bulakbasi T. Cytogenetic findings and clinical outcomes of adult acute myeloid leukaemia patients. Clin Exp Med 2007; 7(3): 102–107
- Huang SY, Yao M, Tang JL. Clinical significance of cytogeneticsand interphase fluorescence in situ hybridization analysis in newly diagnosed multiple myeloma in Taiwan. Ann Oncol 2005; 16(9): 1530–1538.
- Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol 2006; 132(4): 410–451.
- Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91(1): 3–21.
- Seidl S, Kaufmann H, Drach J. New insights into the pathophy-siology of multiple myeloma. Lancet Oncol 2003; 4(9): 557–564.
- Schmidt-Wolf IG, Glasmacher A, Hahn-Ast C. Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance. Cancer Genet Cytogenet 2006; 167(1): 20–25.
- Magrangeas F, Cormier ML, Descamps G. Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood 2004; 103(10): 3869–3875.
- Terpos E, Eleutherakis-Papaiakovou V, Dimopoulos MA. Clinical implications of chromosomal abnormalities in multiple myeloma. Leuk Lymphoma 2006; 47(5): 803–814.
- Elnenaei MO, Hamoudi RA, Swansbury J. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes Cancer 2003; 36(1): 99–106.
- Zojer N, Konigsberg R, Ackermann J. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000; 95(6): 1925–1930.